MPO-DNA

other

Circulating NET component serving as marker of pathogenic neutrophil activation and thrombo-inflammatory burden post-MI.

Pathway placement

Cascade stepPlaque inflammation

Confidencehigh

RationaleNET burden marker reflecting myeloperoxidase-containing neutrophil extracellular traps.

Also acts inPlatelet activation

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)+1.9

Confounder panel (Type-II drivers)

No confounder evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST)

Method / principle

Method depends on analyte chemistry

Reagent / substrate

Analyte-specific

Platform

Variable

Turnaround · availability

Research · Research